GAITHERSBURG, Md. and
SOUTH SAN FRANCISCO, Calif.,
March 24, 2020 /PRNewswire/
-- MaxCyte, Inc., a global cell-based therapies and life
sciences company, and Allogene Therapeutics, Inc. (Nasdaq:
ALLO), a clinical-stage biotechnology company pioneering the
development of allogeneic CAR T (AlloCAR T™) therapies for cancer,
today announced a clinical and commercial license agreement. Under
the terms of the agreement, Allogene gains rights to use MaxCyte's
Flow Electroporation® technology and ExPERT™ platform to develop
and advance its AlloCAR T™ candidates through to
commercialization. In return, MaxCyte will receive undisclosed
development, approval and commercial milestones in addition to
other licensing fees. The first two Allogene investigational
therapies intended to utilize this validated gene editing and
advanced proprietary cell manufacturing technology are directed at
CD19 and BCMA targets.
MaxCyte's ExPERT instrument family represents the next
generation of leading, clinically validated, electroporation
technology for complex and scalable cellular engineering. By
delivering high transfection efficiency with enhanced
functionality, the ExPERT platform delivers the high-end
performance essential to enable the next wave of biological and
cellular therapeutics. Allogene intends to deploy the MaxCyte
technology to effect the gene editing steps during the production
process. The closed system and high efficiency make it an ideal
addition for GMP operations.
"MaxCyte's ExPERT platform has become the industry standard in
electroporation technology and allows us to increase efficiency and
improve yield, which is a critical component to the value
proposition of our AlloCAR T™ therapies," said Alison Moore, Ph.D., Chief Technical Officer of
Allogene.
Doug Doerfler, President &
CEO of MaxCyte, said: "We're honored to partner with Allogene to
help unlock the full potential of its next-generation allogeneic
CAR T therapies through utilization of our Flow Electroporation®
technology and ExPERT™ platform."
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. Through its life sciences business,
MaxCyte biopharmaceutical partners leverage the Company's Flow
Electroporation® Technology to advance the development of
innovative, transformative medicines, particularly in cell
therapy. MaxCyte has placed its technology worldwide, including
with all of the top ten global biopharmaceutical companies. The
Company now has more than 100 partnered programme licenses in cell
therapy with more than 70 licensed for clinical use. The Company
has now entered into nine clinical/commercial license partnerships
with leading cell therapy developers and the potential
pre-commercial milestones from these relationships now
significantly exceeds $650 million.
With its robust delivery technology platform, MaxCyte helps its
partners to unlock the full potential of their therapeutic
products. MaxCyte is also developing novel CARMA therapies, with
its first drug candidate in a Phase I clinical trial. CARMA is
MaxCyte's mRNA-based proprietary therapeutic platform for
autologous cell therapy for the treatment of solid cancers. MaxCyte
has established CARMA Cell Therapies as a wholly owned
subsidiary to facilitate independent investment and new
partnerships to advance the CARMA platform. For more information,
visit www.maxcyte.com.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage
biotechnology company pioneering the development of allogeneic
chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.
Led by a world-class management team with significant experience in
cell therapy, Allogene is developing a pipeline of "off-the-shelf"
CAR T cell therapy candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and at greater
scale to more patients. For more information, please visit
www.allogene.com, and follow @AllogeneTx on Twitter and
LinkedIn.
Cautionary Note on Forward-Looking Statements
This
press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The press release may, in some cases, use terms
such as "predicts," "believes," "potential," "proposed,"
"continue," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should" or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Forward-looking statements
include statements regarding intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things: the ability of the MaxCyte technology and platform to
increase efficiency and improve yield of AlloCAR T™ therapies, the
ability to manufacture AlloCAR T™ therapies, the ability to
progress AlloCAR T therapies through clinical trials and obtain
regulatory approval, and the potential benefits of AlloCAR T™
therapy. Various factors may cause differences between Allogene's
expectations and actual results as discussed in greater detail in
Allogene's filings with the Securities and Exchange Commission
(SEC), including without limitation in its Form 10-K for the year
ended December 31, 2019. Any
forward-looking statements that are made in this press release
speak only as of the date of this press release. Allogene assumes
no obligation to update the forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
This announcement contains inside information for the
purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).
AlloCAR T™ is a trademark of Allogene Therapeutics,
Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/maxcyte-and-allogene-therapeutics-sign-clinical-and-commercial-license-agreement-to-enable-the-advancement-of-allogeneic-car-t-allocar-t-therapies-301028499.html
SOURCE MaxCyte, Inc.